Today the dispute settlement panel formed under the United States-Mexico-Canada Agreement (USMCA) issued a final ruling related to Mexico's restrictions on the importation of genetically modified (GM) ...

Before we head out for the holidays, we're back with some breaking news about a few of BIO's legislative priorities. Happy Holidays and Happy New Year! We'll see you in 2025 (unless there's major ...

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...

Today, the Biotechnology Innovation Organization (BIO) named Sarah Alspach as its new executive vice president and chief communications officer. Alspach, a communications veteran, will join BIO’s ...

John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), today released the following statement ahead of an expected vote in the U.S. House of Representatives on a ...

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities. "Manufacturers should have the choice to effectuate ...

Prior to the case study exercise, Silas Buchanan Founding CEO of the Institute for eHealth Equity will provide a framework to use for underserved-community outreach and how to avoid failure points. He ...

Hope you enjoyed the holiday weekend. We’re back with BIO’s Bio.News series on the problems with PBMs, plus a recap of BIO’s IP Counsels Committee Conference and more news you need to know. (573 words ...

Javeed Froozan’s corporate development experience spans over 25 years in early stage, growth, and large biopharma and health tech firms. This includes acquiring companies, products and technologies in ...

Before you begin your Thanksgiving prep, we recap last week's Clinical Trial Diversity Summit, how the "faceless middleman" is raising your healthcare costs, and promising news from USDA. (890 words, ...

Today, we explore BIO’s recommendations for how CMS can safeguard patient access under Medicare Part D, along with insights on a California Supreme Court case that could affect the complex drug ...

A busy Monday brings louder calls for PBM reform, plus a report on U.S. biotech economic output and jobs, news on avian flu and plant biotech regulations, and more. (834 words, 4 minutes, 10 seconds) ...